• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎诊断、疫苗和治疗药物的最新进展。

Current development of COVID-19 diagnostics, vaccines and therapeutics.

机构信息

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Research Center of Chinese Jujube, Hebei Agriculture University, Baoding, China.

出版信息

Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.

DOI:10.1016/j.micinf.2020.05.001
PMID:32387332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7200352/
Abstract

A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection.

摘要

一种新型冠状病毒,被指定为 SARS-CoV-2,于 2019 年 12 月在中国湖北省武汉市首次出现。病例数量的迅速增加引起了全球恐慌。在这篇综述中,我们描述了一些目前应用的诊断方法,以及治疗和疫苗,以预防、治疗和控制 SARS-CoV-2 感染的进一步爆发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/820c/7200352/523fb67a2c04/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/820c/7200352/523fb67a2c04/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/820c/7200352/523fb67a2c04/gr1_lrg.jpg

相似文献

1
Current development of COVID-19 diagnostics, vaccines and therapeutics.新型冠状病毒肺炎诊断、疫苗和治疗药物的最新进展。
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
2
Drug Discovery Strategies for SARS-CoV-2.针对 SARS-CoV-2 的药物研发策略。
J Pharmacol Exp Ther. 2020 Oct;375(1):127-138. doi: 10.1124/jpet.120.000123. Epub 2020 Jul 28.
3
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病(COVID-19):小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
4
Tracking a Vaccine and Developing Therapeutics for COVID-19.追踪新冠疫苗及研发新冠治疗方法
Dimens Crit Care Nurs. 2020 Nov/Dec;39(6):293-297. doi: 10.1097/DCC.0000000000000447.
5
A vaccine is not too far for COVID-19.针对新冠病毒的疫苗已为时不远。
J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.
6
COVID-19: The Need for Immunoprevention at Industrial Scale.新型冠状病毒肺炎:大规模免疫预防的必要性
Am J Trop Med Hyg. 2020 Jun;102(6):1151. doi: 10.4269/ajtmh.20-0239.
7
Development of vaccines for SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗的研发
F1000Res. 2020 Aug 17;9. doi: 10.12688/f1000research.25998.1. eCollection 2020.
8
Emergence of novel coronavirus and progress toward treatment and vaccine.新型冠状病毒的出现以及治疗和疫苗的研发进展。
Rev Med Virol. 2020 Jul;30(4):e2116. doi: 10.1002/rmv.2116. Epub 2020 Jun 4.
9
COVID-19 vaccine trials in Africa.非洲的新冠疫苗试验。
Lancet Respir Med. 2020 Nov;8(11):e79-e80. doi: 10.1016/S2213-2600(20)30401-X. Epub 2020 Sep 5.
10
COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.COVID-19,一种新兴的冠状病毒感染:在疫苗、免疫疗法和治疗药物的设计和开发方面的进展和前景。
Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238. doi: 10.1080/21645515.2020.1735227. Epub 2020 Mar 18.

引用本文的文献

1
Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication.了解血管紧张素转换酶2(ACE2)在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的关键作用:从结构/功能到治疗意义。
Egypt J Med Hum Genet. 2022;23(1):103. doi: 10.1186/s43042-022-00314-9. Epub 2022 Jun 19.
2
Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines.对SARS-CoV-2的T细胞介导免疫反应的最新见解:迈向高效可靠疫苗的一步。
Vaccines (Basel). 2023 Jan 1;11(1):101. doi: 10.3390/vaccines11010101.
3
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).

本文引用的文献

1
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
2
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.针对新兴致病性人类冠状病毒的亚单位疫苗
Front Microbiol. 2020 Feb 28;11:298. doi: 10.3389/fmicb.2020.00298. eCollection 2020.
3
SARS-CoV-2 Vaccines: Status Report.SARS-CoV-2 疫苗:现状报告。
新型冠状病毒病(COVID-19)的现有药物和预防性疫苗概述。
Cell Mol Biol Lett. 2022 May 13;27(1):38. doi: 10.1186/s11658-022-00339-3.
4
An epidemiological study and trend analysis of laboratory confirmed COVID-19 cases among children in North India.印度北部儿童实验室确诊新冠病例的流行病学研究及趋势分析
J Family Med Prim Care. 2022 Feb;11(2):542-546. doi: 10.4103/jfmpc.jfmpc_1239_21. Epub 2022 Feb 16.
5
A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.关于可采购的新冠疫苗差异的综合调查。
AAPS PharmSciTech. 2022 Mar 21;23(4):95. doi: 10.1208/s12249-022-02247-3.
6
Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.用于检测导致 COVID-19 大流行的 SARS-CoV-2 感染的诊断检测和技术进展。
Anal Bioanal Chem. 2022 Apr;414(9):2903-2934. doi: 10.1007/s00216-022-03918-7. Epub 2022 Feb 25.
7
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.科瓦克辛和科维希尔德的免疫原性和反应原性疗效:比较评价。
Immunol Res. 2022 Jun;70(3):289-315. doi: 10.1007/s12026-022-09265-0. Epub 2022 Feb 22.
8
An Analysis COVID-19 in Mexico: a Prediction of Severity.墨西哥 COVID-19 分析:严重程度预测。
J Gen Intern Med. 2022 Feb;37(3):624-631. doi: 10.1007/s11606-021-07235-0. Epub 2022 Jan 7.
9
Advances in the design and development of SARS-CoV-2 vaccines.SARS-CoV-2 疫苗的设计和开发进展。
Mil Med Res. 2021 Dec 16;8(1):67. doi: 10.1186/s40779-021-00360-1.
10
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview.基于RNA的疫苗在抗击新冠疫情中的重要性:概述
Vaccines (Basel). 2021 Nov 17;9(11):1345. doi: 10.3390/vaccines9111345.
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.
4
High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2.高传染性和严重急性呼吸综合征冠状病毒 2 的快速传播。
Emerg Infect Dis. 2020 Jul;26(7):1470-1477. doi: 10.3201/eid2607.200282. Epub 2020 Jun 21.
5
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
6
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
7
The epidemiology, diagnosis and treatment of COVID-19.新型冠状病毒肺炎的流行病学、诊断与治疗。
Int J Antimicrob Agents. 2020 May;55(5):105955. doi: 10.1016/j.ijantimicag.2020.105955. Epub 2020 Mar 28.
8
Emerging prophylaxis strategies against COVID-19.针对新型冠状病毒肺炎的新兴预防策略。
Monaldi Arch Chest Dis. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289.
9
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2(前称 2019-nCoV)感染,该抑制剂针对病毒的刺突蛋白,具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
10
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.